Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib
This study is designed to determine the clinical efficacy and toxicity of ABT 869 in the treatment of subjects with advanced renal cell carcinoma who have previously received treatment with sunitinib.
Advanced Renal Cell Carcinoma
DRUG: ABT-869
Objective Response Rate, From randomization until patient death or alive at 2 years
Progression-free rate, Week 16|Best response rate, From randomization until patient death or alive at 2 years|Time to tumor progression, From randomization until patient death or alive at 2 years|Progression free survival, Radiographic evaluation every month, clinical evaluation every 4 weeks|Overall Survival, Two-year follow-up post study
This study is designed to determine the clinical efficacy and toxicity of ABT 869 in the treatment of subjects with advanced renal cell carcinoma who have previously received treatment with sunitinib.